Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PHARMACEUTICALS

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FENTANYL CRS - * NARC (30 MG)

FENTANYL CRS - * NARC (30 MG)

ND

DISCOVER
ZOLMITRIPTAN IMPURITY A CRS (10 MG)

ZOLMITRIPTAN IMPURITY A CRS (10 MG)

ND

DISCOVER
ACITRETIN FOR IMPURITY A IDENTIFICATION CRS (5 MG)

ACITRETIN FOR IMPURITY A IDENTIFICATION CRS (5 MG)

ND

DISCOVER
SUCCINIC ACID CRS (20 MG)

SUCCINIC ACID CRS (20 MG)

ND

DISCOVER
LACOSAMIDE IMPURITY F CRS (5 MG)

LACOSAMIDE IMPURITY F CRS (5 MG)

NA

DISCOVER
FIPRONIL FOR SYSTEM SUITABILITY CRS (5 MG)

FIPRONIL FOR SYSTEM SUITABILITY CRS (5 MG)

ND

DISCOVER
ZOLMITRIPTAN FOR SYSTEM SUITABILITY CRS (10 MG)

ZOLMITRIPTAN FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
LAVENDER OIL FOR PEAK IDENTIFICATION HRS (500 µL)

LAVENDER OIL FOR PEAK IDENTIFICATION HRS (500 µL)

ND

DISCOVER
SEVOFLURANE FOR SYSTEM SUITABILITY CRS (0.5 ML)

SEVOFLURANE FOR SYSTEM SUITABILITY CRS (0.5 ML)

ND

DISCOVER
HUMAN IMMUNOGLOBULIN FOR ANTICOMPLEMENTARY ACTIVITY BRP (10

HUMAN IMMUNOGLOBULIN FOR ANTICOMPLEMENTARY ACTIVITY BRP (10

ND

DISCOVER
NICOTINIC ACID FOR EQUIPMENT QUALIFICATION CRS (250 MG)

NICOTINIC ACID FOR EQUIPMENT QUALIFICATION CRS (250 MG)

ND

DISCOVER
LEAD SOLUTION CRS (10 ML)

LEAD SOLUTION CRS (10 ML)

ND

DISCOVER